|Bid||0.00 x 900|
|Ask||0.70 x 800|
|Day's Range||0.23 - 0.24|
|52 Week Range||0.15 - 0.65|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
After reading Hemispherx Biopharma Inc’s (AMEX:HEB) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past andRead More...
With the stock up 50% over the past 3 months, we believe HEB (HEB) is starting to look like an attractive investment. Since our prior report (November 14, 2017), Hemispherx has made some progress in their Ampligen product development cycle that could potentially prove positive for their stock. ➢ Hemispherx obtained ANMAT approval in Argentina, one of South America's largest markets, in August 2017. Ampligen is available in Europe through an Early Access Program (EAP). In the U.S., Ampligen has undergone two randomized, placebo-controlled pivotal trials. The firm is currently focused on preparing an NDA and confirmatory trial for Ampligen. Meanwhile, Ampligen is available for patients under a cost recovery program (compassionate care) – which means that Hemispherx cannot make a profit on Ampligen sales but can recover its costs. Hemispherx received an approval from the FDA to increase the price of one vial from $75 to $200.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Hemispherx Biopharma, Inc. Here are 5 ETFs with the largest exposure to HEB-US. Comparing the performance and risk of Hemispherx Biopharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Hemispherx Biopharma, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Hemispherx Biopharma, Inc. – Sarepta Therapeutics, Inc., Gilead Sciences, Inc., Pfizer Inc., Baxter International Inc., Merck & Co., Inc., Valeant Pharmaceuticals International Inc, GlaxoSmithKline plc Sponsored ADR and ... Read more (Read more...)
Currently, commercialization efforts for both drugs have been hampered for different reasons. The company faced some manufacturing hurdles related to Alferon. However, the company has already taken steps towards increasing efficiency for production of Alferon. The FDA rejected the NDA for Ampligen. However, the company is working towards addressing the concerns raised by the FDA. The company is also open to collaborative opportunities including out-licensing, co-research, co-development, co-promotion as well as co-marketing their product candidates. Overall, we do see some significant headwinds for Hemispherix in the near term, however we believe there is a large market potential for the drugs and see significant value if they are able to overcome current roadblocks.
Hemispherx Biopharma Inc (AMEX:HEB), a USD$10.43M small-cap, operates in the healthcare industry, which faces key trends such as rising demand fuelled by an aging population and the growing prevalence ofRead More...
As the USD $9.07M market cap Hemispherx Biopharma Inc (AMEX:HEB) released another year of negative earnings, investors may be on edge waiting for breakeven. The single most important question toRead More...